Deleted Tweets From Scott Gottlieb, R-D.C.

RT @SeanKhozin: Congrats to @_bakulpatel for well-deserved recognition! #FDAPrecert is a gateway for capturing the full potential of #digit… QT @StephCaccomo: Congrats @_bakulpatel for being named @MedTechDive Person of the Year for all of his work on #FDAPrecert at… https://t.co/FwMHqGfE1S)

1/2 Check out #FDA’s new video resource to help stakeholders understand menu labeling regulations. It explains how food establishments can best comply with requirements to provide consumers important nutrition and calorie info on menus: https://t.co/RAHzI2svEM

2/2 Today’s video release is a continuation of #FDA’s work educating and working with food establishments to help them comply with the new regulations. We are hopeful that the new labels will help consumers make more informed choices about their diets and health.

When generic applications require multiple cycles of review it delays patient access to medicines and is resource intensive. #FDA finalized guidance that will assist in correcting deficiencies to help reduce applications that require multiple reviews. https://t.co/23vPjOOEVH

Today, #FDA finalized guidance which provides recommendations to industry on post-complete response letter meetings with the agency for the purpose of clarifying deficiencies identified in complete response letters. https://t.co/23vPjOOEVH https://t.co/8vxm6d3Sxp

RT @SGottliebFDA: THREAD: New #FDA draft guidance issued today is aimed at accelerating the development of safe and effective treatme… https://t.co/Bxa10ERYvq

Over the next several months, #FDA will continue to advance guidance to assist industry in submitting complete applications that are ready for the agency’s review so more high-quality generics can get to patients. https://t.co/23vPjOOEVH

Dog owners: Here is a list of dry dog foods recalled for high levels of vitamin D that can cause kidney failure and death. This is an evolving situation and this list may grow. https://t.co/7JfXHC9A1R https://t.co/ZeHnzJtkTk

#FDA advances new policy to encourage more effective engagement with generic drug applicants to improve efficiency of their development process. For 2019 we’re focusing on new policies that can promote more efficient, lower cost generic drug development. https://t.co/WyPNo6Zrod

This study of dental painkillers and the risk to young people of opioid addiction provides more evidence why we must decrease unnecessary and inappropriate exposure to opioids and ensure rational prescribing through evidence-based prescribing guidelines https://t.co/yFviCIGbQN

RT @tmprowell: Not too shabby, as we say in our family for a job very well done. #leusm #lymsm #ayacsm #mmsm https://t.co/qjDpcBekMs QT @FDAOncology: 2018 saw 32 #FDAapprovals in #hematology including 12 NMEs & 5 #biosimilars. 8 had pediatric indications. 6 were fo… https://t.co/9WEzAHvSef)

#FDA’s partnership with @Scholastic to provide school administrators and teachers resources to help them engage with students about e-cigarette use is already making an impact. Tens of thousands of educators have downloaded the materials; suggesting a reach of +1M students so far https://t.co/LFhLva2lsK

Congratulations to @ivanoransky on this news and wishing you well in the new role. QT @ivanoransky: Some personal career news: I'm thrilled to be joining the fantastic team at @Medscape. https://t.co/1TO6NklBXU)

RT @FDATobacco: Do you want to help reduce tobacco’s impact on public health? In January, @FDATobacco will call for applications fo… https://t.co/2etYxKwgxr

RT @endpts: FDA issues draft guidance on #NASH #drugdevelopment https://t.co/8MIBOxw9xI by @michael_mezher via @RAPSorg

Today, #FDA has formally recognized a public database that contains information about genes, genetic variants and their relationship to disease, @ClinGenResource https://t.co/edbf4sjB3P

RT @MedResJourno: FDA's decision to formally recognize an NIH genetic database as scientifically valid for diagnostics developers sho… https://t.co/jM8f0WvCBV

#FDA’s commitment to Collaborative Communities recognizes that we serve the American public better when stakeholders in the medical device ecosystem, including FDA, work together to advance science-based solutions to key regulatory principles #FDAVoices https://t.co/PAMm4wzbJq https://t.co/JegLe1EcKG

In April 2018, #FDA issued guidance to accelerate the utilization of these public databases and the development of genetic tests. Our policies encourage data sharing and outline and approach for how developers can use these databases to support clinical claims for tests

Genetic tests are opening up opportunities to segment illnesses into more treatable subsets and enabling the development of more effective, targeted drugs aimed at previously unknown disease categories. Genetic tests can drive transformation in medical care and drug development

RT @SeanKhozin: Congrats to @_bakulpatel for well-deserved recognition! #FDAPrecert is a gateway for capturing the full potential of #digit… QT @StephCaccomo: Congrats @_bakulpatel for being named @MedTechDive Person of the Year for all of his work on #FDAPrecert at… https://t.co/FwMHqGfE1S)

1/2 Check out #FDA’s new video resource to help stakeholders understand menu labeling regulations. It explains how food establishments can best comply with requirements to provide consumers important nutrition and calorie info on menus: https://t.co/RAHzI2svEM

2/2 Today’s video release is a continuation of #FDA’s work educating and working with food establishments to help them comply with the new regulations. We are hopeful that the new labels will help consumers make more informed choices about their diets and health.

When generic applications require multiple cycles of review it delays patient access to medicines and is resource intensive. #FDA finalized guidance that will assist in correcting deficiencies to help reduce applications that require multiple reviews. https://t.co/23vPjOOEVH

Today, #FDA finalized guidance which provides recommendations to industry on post-complete response letter meetings with the agency for the purpose of clarifying deficiencies identified in complete response letters. https://t.co/23vPjOOEVH https://t.co/8vxm6d3Sxp

RT @SGottliebFDA: THREAD: New #FDA draft guidance issued today is aimed at accelerating the development of safe and effective treatme… https://t.co/Bxa10ERYvq

Over the next several months, #FDA will continue to advance guidance to assist industry in submitting complete applications that are ready for the agency’s review so more high-quality generics can get to patients. https://t.co/23vPjOOEVH

Dog owners: Here is a list of dry dog foods recalled for high levels of vitamin D that can cause kidney failure and death. This is an evolving situation and this list may grow. https://t.co/7JfXHC9A1R https://t.co/ZeHnzJtkTk

#FDA advances new policy to encourage more effective engagement with generic drug applicants to improve efficiency of their development process. For 2019 we’re focusing on new policies that can promote more efficient, lower cost generic drug development. https://t.co/WyPNo6Zrod

This study of dental painkillers and the risk to young people of opioid addiction provides more evidence why we must decrease unnecessary and inappropriate exposure to opioids and ensure rational prescribing through evidence-based prescribing guidelines https://t.co/yFviCIGbQN

RT @tmprowell: Not too shabby, as we say in our family for a job very well done. #leusm #lymsm #ayacsm #mmsm https://t.co/qjDpcBekMs QT @FDAOncology: 2018 saw 32 #FDAapprovals in #hematology including 12 NMEs & 5 #biosimilars. 8 had pediatric indications. 6 were fo… https://t.co/9WEzAHvSef)

#FDA’s partnership with @Scholastic to provide school administrators and teachers resources to help them engage with students about e-cigarette use is already making an impact. Tens of thousands of educators have downloaded the materials; suggesting a reach of +1M students so far https://t.co/LFhLva2lsK

Congratulations to @ivanoransky on this news and wishing you well in the new role. QT @ivanoransky: Some personal career news: I'm thrilled to be joining the fantastic team at @Medscape. https://t.co/1TO6NklBXU)

RT @FDATobacco: Do you want to help reduce tobacco’s impact on public health? In January, @FDATobacco will call for applications fo… https://t.co/2etYxKwgxr

RT @endpts: FDA issues draft guidance on #NASH #drugdevelopment https://t.co/8MIBOxw9xI by @michael_mezher via @RAPSorg

Today, #FDA has formally recognized a public database that contains information about genes, genetic variants and their relationship to disease, @ClinGenResource https://t.co/edbf4sjB3P

RT @MedResJourno: FDA's decision to formally recognize an NIH genetic database as scientifically valid for diagnostics developers sho… https://t.co/jM8f0WvCBV

#FDA’s commitment to Collaborative Communities recognizes that we serve the American public better when stakeholders in the medical device ecosystem, including FDA, work together to advance science-based solutions to key regulatory principles #FDAVoices https://t.co/PAMm4wzbJq https://t.co/JegLe1EcKG

In April 2018, #FDA issued guidance to accelerate the utilization of these public databases and the development of genetic tests. Our policies encourage data sharing and outline and approach for how developers can use these databases to support clinical claims for tests

Genetic tests are opening up opportunities to segment illnesses into more treatable subsets and enabling the development of more effective, targeted drugs aimed at previously unknown disease categories. Genetic tests can drive transformation in medical care and drug development